Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
Blood ; 111(3): 1004-12, 2008 Feb 01.
Article in English | MEDLINE | ID: mdl-17942754

ABSTRACT

The cytokine BAFF binds to the receptors TACI, BCMA, and BAFF-R on B cells, whereas APRIL binds to TACI and BCMA only. The signaling properties of soluble trimeric BAFF (BAFF 3-mer) were compared with those of higher-order BAFF oligomers. All forms of BAFF bound BAFF-R and TACI, and elicited BAFF-R-dependent signals in primary B cells. In contrast, signaling through TACI in mature B cells or plasmablasts was only achieved by higher-order BAFF and APRIL oligomers, all of which were also po-tent activators of a multimerization-dependent reporter signaling pathway. These results indicate that, although BAFF-R and TACI can provide B cells with similar signals, only BAFF-R, but not TACI, can respond to soluble BAFF 3-mer, which is the main form of BAFF found in circulation. BAFF 60-mer, an efficient TACI agonist, was also detected in plasma of BAFF transgenic and nontransgenic mice and was more than 100-fold more active than BAFF 3-mer for the activation of multimerization-dependent signals. TACI supported survival of activated B cells and plasmablasts in vitro, providing a rational basis to explain the immunoglobulin deficiency reported in TACI-deficient persons.


Subject(s)
B-Cell Activating Factor/metabolism , B-Lymphocytes/cytology , B-Lymphocytes/metabolism , Lymphocyte Activation , Transmembrane Activator and CAML Interactor Protein/metabolism , Tumor Necrosis Factor Ligand Superfamily Member 13/metabolism , Amino Acid Sequence , Animals , Antibodies/immunology , Antibody Formation/immunology , B-Cell Activating Factor/chemistry , B-Cell Activating Factor/genetics , B-Cell Activation Factor Receptor/immunology , B-Cell Activation Factor Receptor/metabolism , B-Lymphocytes/immunology , Cell Line , Cell Proliferation , Histocompatibility Antigens Class II/immunology , Humans , Immunoglobulins/biosynthesis , Immunoglobulins/immunology , Ligands , Mice , Mice, Knockout , Mice, Transgenic , Molecular Sequence Data , Sequence Alignment , Signal Transduction , Spleen/immunology , Transmembrane Activator and CAML Interactor Protein/deficiency , Transmembrane Activator and CAML Interactor Protein/genetics , Tumor Necrosis Factor Ligand Superfamily Member 13/genetics , Up-Regulation
3.
Am J Hum Genet ; 81(5): 1050-6, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17924345

ABSTRACT

Patients with defective ectodysplasin A (EDA) are affected by X-linked hypohidrotic ectodermal dysplasia (XLHED), a condition characterized by sparse hair, inability to sweat, decreased lacrimation, frequent pulmonary infections, and missing and malformed teeth. The canine model of XLHED was used to study the developmental impact of EDA on secondary dentition, since dogs have an entirely brachyodont, diphyodont dentition similar to that in humans, as opposed to mice, which have only permanent teeth (monophyodont dentition), some of which are very different (aradicular hypsodont) than brachyodont human teeth. Also, clinical signs in humans and dogs with XLHED are virtually identical, whereas several are missing in the murine equivalent. In our model, the genetically missing EDA was compensated for by postnatal intravenous administration of soluble recombinant EDA. Untreated XLHED dogs have an incomplete set of conically shaped teeth similar to those seen in human patients with XLHED. After treatment with EDA, significant normalization of adult teeth was achieved in four of five XLHED dogs. Moreover, treatment restored normal lacrimation and resistance to eye and airway infections and improved sweating ability. These results not only provide proof of concept for a potential treatment of this orphan disease but also demonstrate an essential role of EDA in the development of secondary dentition.


Subject(s)
Disease Models, Animal , Ectodermal Dysplasia/therapy , Ectodysplasins/administration & dosage , Ectodysplasins/pharmacology , Genetic Diseases, X-Linked/therapy , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacology , Animals , Animals, Newborn , Dentition , Dogs , Female , Humans , Injections, Intravenous , Lacrimal Apparatus/drug effects , Lacrimal Apparatus/metabolism , Male , Mandible/diagnostic imaging , Mandible/drug effects , Mice , Mucociliary Clearance/drug effects , Radiography , Sweating/drug effects , Treatment Outcome
4.
J Biol Chem ; 281(20): 13964-71, 2006 May 19.
Article in English | MEDLINE | ID: mdl-16547002

ABSTRACT

Ligands of the tumor necrosis factor superfamily (TNFSF) (4-1BBL, APRIL, BAFF, CD27L, CD30L, CD40L, EDA1, EDA2, FasL, GITRL, LIGHT, lymphotoxin alpha, lymphotoxin alphabeta, OX40L, RANKL, TL1A, TNF, TWEAK, and TRAIL) bind members of the TNF receptor superfamily (TNFRSF). A comprehensive survey of ligand-receptor interactions was performed using a flow cytometry-based assay. All ligands engaged between one and five receptors, whereas most receptors only bound one to three ligands. The receptors DR6, RELT, TROY, NGFR, and mouse TNFRH3 did not interact with any of the known TNFSF ligands, suggesting that they either bind other types of ligands, function in a ligand-independent manner, or bind ligands that remain to be identified. The study revealed that ligand-receptor pairs are either cross-reactive between human and mouse (e.g. Tweak/Fn14, RANK/RANKL), strictly species-specific (GITR/GITRL), or partially species-specific (e.g. OX40/OX40L, CD40/CD40L). Interestingly, the receptor binding patterns of lymphotoxin alpha and alphabeta are redundant in the human but not in the mouse system. Ligand oligomerization allowed detection of weak interactions, such as that of human TNF with mouse TNFR2. In addition, mouse APRIL exists as two different splice variants differing by a single amino acid. Although human APRIL does not interact with BAFF-R, the shorter variant of mouse APRIL exhibits weak but detectable binding to mouse BAFF-R.


Subject(s)
Receptors, Tumor Necrosis Factor/metabolism , Tumor Necrosis Factors/metabolism , Alternative Splicing , Amino Acid Sequence , Animals , Cell Membrane/metabolism , Humans , Ligands , Mice , Mice, Inbred C57BL , Molecular Sequence Data , Protein Binding , Sequence Homology, Amino Acid , Species Specificity
5.
Biochemistry ; 45(7): 2006-13, 2006 Feb 21.
Article in English | MEDLINE | ID: mdl-16475789

ABSTRACT

The oligomeric state of BAFF (B cell activing factor), a tumor necrosis factor (TNF) family cytokine that plays a critical role in B cell development and survival, has been the subject of recent debate. Myc-tagged BAFF starting at residue Gln136 was previously reported to crystallize as trimers at pH 4.5, whereas a histidine-tagged construct of BAFF, starting at residue Ala134, formed a virus-like cluster containing 60 monomers when crystallized at pH 9.0. The formation of the BAFF 60-mer was pH dependent, requiring pH >or= 7.0. More recently, 60-mer formation was suggested to be artificially induced by the histidine tag, and it was proposed that BAFF, like all other TNF family members, is trimeric. We report here that a construct of BAFF with no amino-terminal tag (Ala134-BAFF) can form a 60-mer in solution. Using size exclusion chromatography and static light scattering to monitor trimer to 60-mer ratios in BAFF preparations, we find that 60-mer formation is pH-dependent and requires histidine 218 within the DE loop of BAFF. Biacore measurements established that the affinity of Ala134-BAFF for the BAFF receptor BAFFR/BR3 is similar to that of myc-Gln136-BAFF, which is exclusively trimeric in solution. However, Ala134-BAFF is more efficacious than myc-Gln136-BAFF in inducing B cell proliferation in vitro. We additionally show that BAFF that is processed and secreted by 293T cells transfected with full-length BAFF, or by a histiocytic lymphoma cell line (U937) that expresses BAFF endogenously, forms a pH-dependent 60-mer in solution. Our results indicate that the formation of the 60-mer in solution by the BAFF extracellular domain is an intrinsic property of the protein, and therefore that this more active form of BAFF may be physiologically relevant.


Subject(s)
Membrane Proteins/physiology , Protein Structure, Quaternary , Tumor Necrosis Factor-alpha/physiology , Animals , B-Cell Activating Factor , Chromatography, Gel , Humans , Hydrogen-Ion Concentration , Light , Mice , Molecular Weight , Pichia/metabolism , Scattering, Radiation
6.
J Exp Med ; 201(9): 1375-83, 2005 May 02.
Article in English | MEDLINE | ID: mdl-15851487

ABSTRACT

B cell activating factor of the tumor necrosis factor (TNF) family (BAFF) and a proliferation-inducing ligand (APRIL) are closely related ligands within the TNF superfamily that play important roles in B lymphocyte biology. Both ligands share two receptors--transmembrane activator and calcium signal--modulating cyclophilin ligand interactor (TACI) and B cell maturation antigen (BCMA)--that are predominantly expressed on B cells. In addition, BAFF specifically binds BAFF receptor, whereas the nature of a postulated APRIL-specific receptor remains elusive. We show that the TNF homology domain of APRIL binds BCMA and TACI, whereas a basic amino acid sequence (QKQKKQ) close to the NH2 terminus of the mature protein is required for binding to the APRIL-specific "receptor." This interactor was identified as negatively charged sulfated glycosaminoglycan side chains of proteoglycans. Although T cell lines bound little APRIL, the ectopic expression of glycosaminoglycan-rich syndecans or glypicans conferred on these cells a high binding capacity that was completely dependent on APRIL's basic sequence. Moreover, syndecan-1-positive plasma cells and proteoglycan-rich nonhematopoietic cells displayed high specific, heparin-sensitive binding to APRIL. Inhibition of BAFF and APRIL, but not BAFF alone, prevented the survival and/or the migration of newly formed plasma cells to the bone marrow. In addition, costimulation of B cell proliferation by APRIL was only effective upon APRIL oligomerization. Therefore, we propose a model whereby APRIL binding to the extracellular matrix or to proteoglycan-positive cells induces APRIL oligomerization, which is the prerequisite for the triggering of TACI- and/or BCMA-mediated activation, migration, or survival signals.


Subject(s)
B-Lymphocytes/metabolism , Membrane Proteins/metabolism , Models, Biological , Nuclear Proteins/metabolism , Proteoglycans/metabolism , Receptors, Tumor Necrosis Factor/metabolism , Animals , B-Cell Activating Factor , B-Cell Activation Factor Receptor , B-Cell Maturation Antigen , Cell Line , Cell Movement/genetics , Cell Proliferation , Flow Cytometry , Heparin/metabolism , Humans , Immunoprecipitation , Mice , Plasma Cells/metabolism , Protein Binding , Protein Structure, Tertiary , Transfection , Transmembrane Activator and CAML Interactor Protein , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...